Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis

Researchers from the Cincinnati Children's Hospital Medical Center observed a statistically significant increase in mean height, weight, and body mass index (BMI) percentiles in patients with juvenile idiopathic arthritis (JIA) who were treated with etanercept or etanercept plus methotrexate (MTX). JIA patients treated with MTX alone did not display an increase in growth percentiles.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

New primary care models needed to improve care and outcomes for older adults

In an article published in November 3 edition of Journal of the American Medical Association (JAMA), Chad Boult, MD, MPH, MBA, professor of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health, calls for key improvements to primary care in order to improve the health of the nation's most costly patients-older adults with multiple chronic conditions.

3 Nov 2010

APS summit focuses on Antiphospholipid Syndrome research

Antiphospholipid Syndrome (APS) is a condition that may be responsible for up to one-third of strokes in people under age 50, up to one-fifth of all cases of blood clots in large veins, and one-quarter of recurrent miscarriages. Nonetheless, relatively few randomized clinical trials have been conducted involving people with APS, and those completed have included small numbers of participants.

3 Nov 2010

Arthritis Foundation urges FDA to expeditiously create regulatory pathway for biosimilars

Arthritis Foundation patient advocate, Jan Wyatt, PhD, will provide oral testimony on behalf of the approximately 4 million Americans with inflammatory arthritis at a Food and Drug Administration (FDA) hearing today. The hearing will focus on issues and challenges associated with an approval pathway for biologic products that are highly similar "biosimilar" or interchangeable with FDA-licensed products.

3 Nov 2010

Amgen outlines key recommendations for implementing approval pathway for biosimilars

Amgen Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to establish approval standards that ensure patient safety and follow a science-based approach.

3 Nov 2010

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand Pharmaceuticals Incorporated today announced it has been awarded $1,955,834 in immediately available funds from the U.S. government under HR: 3590 - Patient Protection and Affordable Care Act. The award comprises separate payments of approximately $245,000 for each of eight drug development programs at Ligand.

2 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded four Therapeutic Discovery Project (TDP) grants, totaling $977,917, by the United States Internal Revenue Service (IRS) as part of the Patient Protection and Affordable Care Act of 2010.

2 Nov 2010

Rigel third quarter net income increases to $50.4 million

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010.

2 Nov 2010

Eye transformer impacts JAK/STAT-signaling pathway response with microbial challenge

Scientists are keeping their eye on a new discovery published in the November 2011 print issue of the FASEB Journal (http://www.fasebj.org) that explains what causes some genes to go out of control. Scientists have identified a "cellular switch," called eye transformer, that controls the flow of information from chemical signals outside of the cell to genes in the cell nucleus.

2 Nov 2010

FDA selects Rochester to lead initiative to identify improved pain treatments

Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.

2 Nov 2010

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

The American Association of Acupuncture and Oriental Medicine (AAAOM) and the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) are collaborating to respond to a recent report by British professor Edzard Ernst, published in The Guardian, claiming improperly trained acupuncture treatments have been the cause of deaths over the past 45 years.

2 Nov 2010

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Almirall, S.A. and Ironwood Pharmaceuticals, Inc. today announced positive top-line results from a 26-week pivotal Phase 3 clinical trial assessing the efficacy and safety of once-daily dosing of linaclotide 266 mcg in patients with irritable bowel syndrome with constipation (IBS-C).

2 Nov 2010

Arthritis drugs also prevent post-operative cognitive decline: Study

Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive problems after surgery, according to a new study by researchers at Imperial College London and University of California, San Francisco (UCSF).

2 Nov 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Phase III study suggests CYCLOSET tablets improve glycemic control

Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis

Bortezomib reduces inflammation and promotes bone healing in arthritis models

New primary care models needed to improve care and outcomes for older adults

APS summit focuses on Antiphospholipid Syndrome research

Arthritis Foundation urges FDA to expeditiously create regulatory pathway for biosimilars

Amgen outlines key recommendations for implementing approval pathway for biosimilars

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

GSK's Revolade receives Japanese approval for treatment of chronic ITP

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

Rigel third quarter net income increases to $50.4 million

Eye transformer impacts JAK/STAT-signaling pathway response with microbial challenge

FDA selects Rochester to lead initiative to identify improved pain treatments

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Arthritis drugs also prevent post-operative cognitive decline: Study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in